Quality of life and pain in patients with thalidomide embryopathy in Japan.
catastrophizing
mental health
pain
quality of life
thalidomide embryopathy
Journal
Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
30
06
2020
accepted:
31
07
2020
pubmed:
8
9
2020
medline:
8
6
2021
entrez:
7
9
2020
Statut:
ppublish
Résumé
The aim of this study was to assess psychological/psychiatric problems and quality of life (QOL) in patients with thalidomide embryopathy (TE), with a specific focus on pain, including pain severity and the effects of coping strategies for pain. A questionnaire survey was conducted to evaluate the severity of pain experienced by patients with TE, pain management strategies, time perspective, mental health status, and QOL. Of 67 patients with TE who underwent a health checkup, 51 respondents who gave valid responses were included in analysis. GHQ-28 suggested that 41.2% of respondents appeared to potentially have psychiatric disorders. The mean scores of QOL were still within a normal range. There is no significant differences were found between limb disability group and hearing impairment group in QOL or mental health status. About 82.4% of respondents reported that they experience physical pain, and the use of the cognitive coping strategy "catastrophizing" to cope with pain was significantly associated with mental health status and QOL. This study demonstrate that although some patients with TE have some form of mental health problem, they still maintain a normal range QOL despite their disabilities. In addition, pain was not as strongly associated with mental health problems and QOL as would be expected, and variables such as "catastrophizing" to cope with pain appear to potentially be associated with reduced mental health and QOL.
Sections du résumé
BACKGROUND
The aim of this study was to assess psychological/psychiatric problems and quality of life (QOL) in patients with thalidomide embryopathy (TE), with a specific focus on pain, including pain severity and the effects of coping strategies for pain.
METHODS
A questionnaire survey was conducted to evaluate the severity of pain experienced by patients with TE, pain management strategies, time perspective, mental health status, and QOL. Of 67 patients with TE who underwent a health checkup, 51 respondents who gave valid responses were included in analysis.
RESULTS
GHQ-28 suggested that 41.2% of respondents appeared to potentially have psychiatric disorders. The mean scores of QOL were still within a normal range. There is no significant differences were found between limb disability group and hearing impairment group in QOL or mental health status. About 82.4% of respondents reported that they experience physical pain, and the use of the cognitive coping strategy "catastrophizing" to cope with pain was significantly associated with mental health status and QOL.
CONCLUSION
This study demonstrate that although some patients with TE have some form of mental health problem, they still maintain a normal range QOL despite their disabilities. In addition, pain was not as strongly associated with mental health problems and QOL as would be expected, and variables such as "catastrophizing" to cope with pain appear to potentially be associated with reduced mental health and QOL.
Identifiants
pubmed: 32893502
doi: 10.1002/mgg3.1464
pmc: PMC7667369
doi:
Substances chimiques
Teratogens
0
Thalidomide
4Z8R6ORS6L
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1464Informations de copyright
© 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
Références
CMAJ. 2008 Apr 8;178(8):997-1003
pubmed: 18390942
Br J Gen Pract. 2011 Dec;61(593):e808-20
pubmed: 22137418
Eur Spine J. 2006 Jan;15 Suppl 1:S17-24
pubmed: 16320034
Shinrigaku Kenkyu. 1994 Apr;65(1):54-60
pubmed: 8022129
J Child Orthop. 2016 Dec;10(6):691-703
pubmed: 27854003
Clin J Pain. 2001 Mar;17(1):52-64
pubmed: 11289089
Br J Gen Pract. 2003 Oct;53(495):758-63
pubmed: 14601350
Psychiatry Clin Neurosci. 2014 Jun;68(6):479-86
pubmed: 24548169
Mol Genet Genomic Med. 2020 Nov;8(11):e1464
pubmed: 32893502
Dtsch Arztebl Int. 2017 Mar 10;114(10):168-174
pubmed: 28377012
J Physiother. 2011;57(4):259
pubmed: 22093128
Psychol Med. 1979 Feb;9(1):139-45
pubmed: 424481